Evidence That Ecotropic Murine Leukemia Virus Contamination in TZM-bl Cells Does Not Affect the Outcome of Neutralizing Antibody Assays with Human Immunodeficiency Virus Type 1

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2009 May 29

PMID 19474095

Citations 166

Authors

Emily J Platt

Miroslawa Bilska

Susan L Kozak

David Kabat

David C Montefiori

Affiliations

Soon will be listed here.

Abstract

The TZM-bl cell line that is commonly used to assess neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) was recently reported to be contaminated with an ecotropic murine leukemia virus (MLV) (Y. Takeuchi, M. O. McClure, and M. Pizzato, J. Virol. 82:12585-12588, 2008), raising questions about the validity of results obtained with this cell line. Here we confirm this observation and show that HIV-1 neutralization assays performed with a variety of serologic reagents in a similar cell line that does not harbor MLV yield results that are equivalent to those obtained in TZM-bl cells. We conclude that MLV contamination has no measurable effect on HIV-1 neutralization when TZM-bl cells are used as targets for infection.

Citing Articles

Identification of a novel small-molecule inhibitor of the HIV-1 reverse transcriptase activity with a non-nucleoside mode of action.

Yu K, Shin Y, Kim D, Kim J, Kang J, Singh P Virol J. 2025; 22(1):65.

PMID: 40055750 PMC: 11887385. DOI: 10.1186/s12985-025-02680-3.

QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro.

Galvez N, Sheehan M, Lin A, Cao Y, Lam E, Jackson A Viruses. 2024; 16(8).

PMID: 39205294 PMC: 11360610. DOI: 10.3390/v16081320.

Evaluating HIV-1 Infectivity and Virion Maturation across Varied Producer Cells with a Novel FRET-Based Detection and Quantification Assay.

McGraw A, Hillmer G, Choi J, Narayan K, Mehedincu S, Marquez D Int J Mol Sci. 2024; 25(12).

PMID: 38928103 PMC: 11204348. DOI: 10.3390/ijms25126396.

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.

Joshi V, Claiborne D, Pack M, Power K, Newman R, Batorsky R J Virol. 2024; 98(3):e0172023.

PMID: 38412036 PMC: 10949433. DOI: 10.1128/jvi.01720-23.

Host ZCCHC3 blocks HIV-1 infection and production through a dual mechanism.

Yi B, Tanaka Y, Cornish D, Kosako H, Butlertanaka E, Sengupta P iScience. 2024; 27(3):109107.

PMID: 38384847 PMC: 10879702. DOI: 10.1016/j.isci.2024.109107.

References

Calarese D, Scanlan C, Zwick M, Deechongkit S, Mimura Y, Kunert R . Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003; 300(5628):2065-71. DOI: 10.1126/science.1083182. View

Kabat D, Kozak S, Wehrly K, Chesebro B . Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol. 1994; 68(4):2570-7. PMC: 236734. DOI: 10.1128/JVI.68.4.2570-2577.1994. View

Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

Sather D, Armann J, Ching L, Mavrantoni A, Sellhorn G, Caldwell Z . Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2008; 83(2):757-69. PMC: 2612355. DOI: 10.1128/JVI.02036-08. View

PLATT E, Madani N, Kozak S, Kabat D . Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol. 1997; 71(2):883-90. PMC: 191135. DOI: 10.1128/JVI.71.2.883-890.1997. View

Moore P, Gray E, Choge I, Ranchobe N, Mlisana K, Abdool Karim S . The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol. 2007; 82(4):1860-9. PMC: 2258729. DOI: 10.1128/JVI.02187-07. View

Wang H, Kavanaugh M, North R, Kabat D . Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter. Nature. 1991; 352(6337):729-31. DOI: 10.1038/352729a0. View

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View

Handelin B, Kabat D . Cell surface receptors for murine leukemia viruses: two assays and their implications. Virology. 1985; 140(1):183-7. DOI: 10.1016/0042-6822(85)90458-1. View

10.

Brunel F, Zwick M, Cardoso R, Nelson J, Wilson I, Burton D . Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol. 2006; 80(4):1680-7. PMC: 1367132. DOI: 10.1128/JVI.80.4.1680-1687.2006. View

11.

Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell J, Derdeyn C . Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol. 2006; 81(3):1350-9. PMC: 1797511. DOI: 10.1128/JVI.01839-06. View

12.

He J, Choe S, Walker R, Di Marzio P, MORGAN D, Landau N . Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol. 1995; 69(11):6705-11. PMC: 189580. DOI: 10.1128/JVI.69.11.6705-6711.1995. View

13.

Albritton L, Kim J, Tseng L, Cunningham J . Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses. J Virol. 1993; 67(4):2091-6. PMC: 240296. DOI: 10.1128/JVI.67.4.2091-2096.1993. View

14.

Barbato G, Bianchi E, Ingallinella P, Hurni W, Miller M, Ciliberto G . Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol. 2003; 330(5):1101-15. DOI: 10.1016/s0022-2836(03)00611-9. View

15.

Pantophlet R, Saphire E, Poignard P, Parren P, Wilson I, Burton D . Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol. 2002; 77(1):642-58. PMC: 140633. DOI: 10.1128/jvi.77.1.642-658.2003. View

16.

Scheid J, Mouquet H, Feldhahn N, Seaman M, Velinzon K, Pietzsch J . Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458(7238):636-40. DOI: 10.1038/nature07930. View

17.

PLATT E, Wehrly K, Kuhmann S, Chesebro B, Kabat D . Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998; 72(4):2855-64. PMC: 109730. DOI: 10.1128/JVI.72.4.2855-2864.1998. View

18.

Takeuchi Y, McClure M, Pizzato M . Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol. 2008; 82(24):12585-8. PMC: 2593302. DOI: 10.1128/JVI.01726-08. View

19.

Kozak S, Kabat D . Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production. J Virol. 1990; 64(7):3500-8. PMC: 249616. DOI: 10.1128/JVI.64.7.3500-3508.1990. View

20.

Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J . Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 2007; 4(12):e348. PMC: 2100141. DOI: 10.1371/journal.pmed.0040348. View